Skip to content
Screener

Savara SVRA EPS (Diluted)

EPS (Diluted) at other companies

Innoviva, Inc. logo
Innoviva, Inc.INVA
-$1.14-248%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$0.14-88.4%
XER
Xeris Biopharma Holdings, Inc.XERS
-$0.18-1,700%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$1.05+192%
Upstream Bio, Inc. logo
Upstream Bio, Inc.UPB
-$0.73+1.4%
PVL
Palvella TherapeuticsPVLA
-$1.20-62.2%

Other financials

Income statement

See full
Operating income-$41.0M-30.3%
Net income-$40.2M-32.3%

Balance sheet

See full
Cash & equivalents$41.8M+140%
Total debt$31.2M+5.2%
Total equity$143.7M+19.2%
Total assets$192.1M+17.3%

Cash flow

See full
Operating cash flow-$29.7M-13.3%
CapEx$222.0K+1,380%
Free cash flow-$30.0M-14.1%

Valuation

See full
Market cap$1.04B+71.8%
Enterprise value$1.03B+66.4%

Profitability

See full
Operating margin-19,183.3%—
Net margin-19,305.1%—
FCF margin-15,518.7%—

Returns & leverage

See full
Return on equity-105.5%+7.0pp
Debt / equity0.2×0.0×
Current ratio10.1×-0.9×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Savara’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-344585
Line itemFor the three months ended June 30, 2026For the three months ended June 30, 2025For the six months ended June 30, 2026For the six months ended June 30, 2025
Total other income, net7371,0392,4432,834
Net loss$(40,228)$(30,401)$(77,512)$(57,040)
Net loss per share:
Basic and diluted$(0.16)$(0.14)$(0.31)$(0.26)
Weighted-average common shares outstanding:
Basic and diluted253,569,891216,431,348253,426,018216,289,923
Other comprehensive income (loss):
Gain (loss) on foreign currency translation(71)502(166)774

Cover / Front Matter

FAQ

What is Savara's EPS (diluted)?
Savara (SVRA) reported EPS (diluted) of -$0.16 in Q2 2026.
How has Savara's EPS (diluted) changed year-over-year?
Savara's EPS (diluted) decreased by 14.3% year-over-year, from -$0.14 to -$0.16.
What is the long-term trend for Savara's EPS (diluted)?
Over 4 years (2021 to 2025), Savara's EPS (diluted) has grown at a 11.7% compound annual growth rate (CAGR), from -$0.34 to -$0.53.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Savara's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude